Deutsche Bank
ANIP icon

Deutsche Bank’s ANI Pharmaceuticals ANIP Stock Holding History

Deutsche Bank’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-650
Closed -$47K – 4979
2019
Q3 		$47K Buy
+650
New +$48.6K ﹤0.01% 3960

Other funds holding ANIP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Deutsche Bank's ANIP Position: Q1 2026 in Review

Deutsche Bank reduced its ANI Pharmaceuticals (ANIP) stake by 19% in Q1 2026, selling an estimated $5.69M and leaving 319,675 shares worth $24.6M. The position accounts for 0.01% of the portfolio, ranked #795.

Deutsche Bank first reported a position in ANIP in Q2 2013 and has held it in 50 quarters since. The position peaked at $31M in Q4 2025. 280 funds tracked by Wall St. Rank hold ANIP as of Q1 2026.

  • Deutsche Bank held 319,675 shares of ANI Pharmaceuticals worth $24.6M as of Q1 2026.
  • Deutsche Bank sold 72,901 ANI Pharmaceuticals shares in Q1 2026, an estimated $5.69M.
  • ANI Pharmaceuticals made up 0.01% of Deutsche Bank's portfolio in Q1 2026, its #795 holding.
  • Deutsche Bank first reported a position in ANI Pharmaceuticals in Q2 2013 and has held it in 50 quarters since.
  • Deutsche Bank's ANI Pharmaceuticals position peaked at $31M in Q4 2025.
  • 280 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q1 2026.

Based on Deutsche Bank's 13F filing for Q1 2026, filed 6 May 2026.